Literature DB >> 8101521

Management of neuroleptic malignant syndrome--a series of eight cases.

T Kurien1, K K Rajeev, O C Abraham, S Archana, A M Cherian.   

Abstract

Neuroleptic Malignant Syndrome (NMS) is a rare and life threatening complication of treatment with Neuroleptic medication. Phenothiazine and butyrophenones are most frequently implicated in this syndrome even though there are case reports with other drugs. In this paper we describe the classical presentation of this syndrome in eight cases who had been on either a butyrophenone, a phenothiazine or a combination of these drugs. In addition some of our patients were also on either Lithium and/or Amitrytiline for control of depressive symptoms. Fever, muscule rigidity and elevated CPK are the important criteria for diagnosis and they were noted in all our patients. In addition four of our patients fulfilled five of the six minor criteria laid down by Levenson. Both Sinemet and Bromocriptine were found to be effective in the treatment of seven of the eight cases. However treatment with Dantroline sodium was associated with severe muscle wasting in one of our cases and the drug had to be discontinued. Two of our patients developed suspected myoglobinuria with dark coloured urine and progressive renal failure. One patient died after development of renal failure, pulmonary edema and hyperkalemia as a consequence of this disorders.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8101521

Source DB:  PubMed          Journal:  J Assoc Physicians India        ISSN: 0004-5772


  2 in total

1.  Combination of Steven-Johnson syndrome and neuroleptic malignant syndrome following carbamazepine therapy: a rare occurrence.

Authors:  Bhawna Sharma; Raghavendra Bakki Sannegowda; Pankaj Gandhi; Parul Dubey; Ashok Panagariya
Journal:  BMJ Case Rep       Date:  2013-06-11

2.  Increased risk of occurrence of neuroleptic malignant syndrome on combined treatment with lithium and neuroleptic.

Authors:  P J Alexander; R M Thomas
Journal:  Indian J Psychiatry       Date:  1997-07       Impact factor: 1.759

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.